 |
|
Adherence to HAART: Why Is It So Difficult?
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
We have started an open prospective study in 1997 and a 2-year follow-up
in 1999 to examine the number of pills prescribed, drug intake frequency,
and reasons for nonadherence to highly active antiretroviral therapy (HAART).1 The objective and design of our evaluation is similar
to some aspects of the ATHENA Project.2
Patients with human immunodeficiency virus (HIV) were asked to complete an
anonymous questionnaire about adherence to prescribed HAART in which daily
intake frequency, number of pills to take, and reasons for missed drugs or
intake were specified.
In 1997, 214 patients were included for evaluation (median age, 40 years;
median CD4 cell count, 260/µL; and median viral load, 2500 copies/mL).
Duration on any antiretroviral therapy was a median of 23 months. Of the 214
patients, 30% did not take all prescribed antiretroviral pills for at least
1 day, and 56% deviated from the recommended schedule for at least 1 . . . [Full Text of this Article]
RELATED ARTICLE
Limited Patient Adherence to Highly Active Antiretroviral Therapy for HIV-1 Infection in an Observational Cohort Study
Pythia T. Nieuwkerk, Mirjam A. G. Sprangers, David M. Burger, Richard M. W. Hoetelmans, Patricia W. H. Hugen, Sven A. Danner, Marchina E. van der Ende, Margriet M. E. Schneider, Gerrit Schrey, Pieter L. Meenhorst, Herman G. Sprenger, Robert H. Kauffmann, Marielle Jambroes, Margaret A. Chesney, Frank de Wolf, Joep M. A. Lange, and for the ATHENA Project
Arch Intern Med. 2001;161(16):1962-1968.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Pharmacologic Perspectives for Once-Daily Antiretroviral Therapy
Anderson
The Annals of Pharmacotherapy 2004;38:1924-1934.
ABSTRACT
| FULL TEXT
|
